Quantcast

Latest AIDS Vaccine 200 Stories

2014-09-05 23:05:17

All-volunteer organization that produces annual AV200 cycling fundraiser adds board members and continues planning its 13th event, slated for May 16-17, 2015 Atlanta, Georgia (PRWEB) September 05, 2014 Action Cycling Atlanta, the all-volunteer group which produces the annual AV200 fundraiser, recently added four new Board Members: Chris Arrington, First Vice President, Treasury & Payment Solutions, SunTrust Bank; Scott Drinkard, Director, Learning Technical Training for Children’s...

2011-04-27 15:00:00

ATLANTA, April 27, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCBB: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2011. GeoVax reported a net loss of $606,282 for the three months ended March 31, 2011, compared to $690,789 for the same period in 2010. Net losses were partially offset by grant revenues of $893,002 and $1,338,560 for each period, respectively, related to...

2011-04-07 07:00:00

ATLANTA, April 7, 2011 /PRNewswire/ -- Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14. Dr. Robinson's invited talk, which will run from 11:30 - 11:50 a.m., will cover the topic of recombinant viruses as vaccines. The talk...

2010-01-06 08:00:00

ATLANTA, Jan. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced the appointment of Mark J. Newman, Ph.D. as vice president, research and development. Dr. Newman will be responsible for developing GeoVax's therapeutic HIV vaccine initiative and broadening the GeoVax pipeline....

2009-11-06 08:00:00

ATLANTA, Nov. 6 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update. Robert McNally, Ph.D., President and Chief Executive Officer commented, "We are pleased with our progress during the third...

2009-10-20 03:50:00

PARIS, Oct. 20 /PRNewswire-USNewswire/ -- Detailed results from the Prime-Boost HIV Vaccine Clinical Trial involving more than 16,000 adult volunteers in Thailand show that an investigational HIV vaccine regimen was safe and modestly effective at reducing the rate of HIV infection compared to placebo. These results were presented today by the trial collaborators to researchers gathered at the AIDS Vaccine 2009 Conference in Paris, France and published online by The New England Journal of...

2009-09-14 08:30:00

Atlanta to Serve as Stage for Premier Discussion on HIV Vaccine Development NEW YORK, Sept. 14 /PRNewswire-USNewswire/ -- The Global HIV Vaccine Enterprise (the Enterprise) today announced that the Center for AIDS Research at Emory University (CFAR) in Atlanta, Georgia will serve as Local Host of AIDS Vaccine 2010, the largest and most important global scientific conference focused on AIDS vaccine research. AIDS 2010 is to be held September 28 to October 1, 2010. This annual...

2009-05-18 10:55:00

WASHINGTON, May 18 /PRNewswire-USNewswire/ -- Every nine and a half minutes someone in the United States is infected with HIV. The Centers for Disease Control and Prevention (CDC) estimates that approximately 56,300 individuals became infected with HIV in 2006 alone. There are over 1.1 million people living with the virus in the United States. It is a disease that impacts minority and poor communities disproportionately: African-Americans are seven times more likely to contract HIV, while the...

2009-03-21 18:37:47

Human testing of an AIDS vaccine is moving into its second phase in China, researchers said Saturday. Chinese scientists said they intend to enroll 30 more volunteers for the next round of tests, Xinhua reported. The start of the second phase was marked by a ceremony in Nanning, the capital of south China's Guangxi Zhuang autonomous region, where the first group of 49 volunteers received the experimental vaccine to ward off acquired immune deficiency syndrome in May 2005, the state-run news...

2009-03-12 07:00:00

ATLANTA, March 12 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of an HIV/AIDS vaccine, today announced its financial results for the fourth quarter and year ended December 31, 2008, and provided a summary of recent operational highlights for calendar year 2009 to date. GeoVax reported a net loss of $1,039,217 for the fourth quarter ended December 31, 2008, as compared to a net loss of $1,155,870 for the...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related